TPST Tempest Therapeutics
- 3.440
- -0.100-2.82%
- 3.490
- +0.050+1.45%
Tempest Therapeutics News
Tempest Therapeutics (TPST) Receives a Buy From Scotiabank
Tempest Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target Is $13
Tempest Therapeutics Analyst Ratings
Scotiabank Initiates Coverage On Tempest Therapeutics With Sector Outperform Rating, Announces Price Target of $13
Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects
Tempest Therapeutics Analyst Ratings
Tempest Therapeutics Analyst Ratings
Growth Potential and Strategic Partnerships: Reasons for Aydin Huseynov's Buy Rating on Tempest Therapeutics
Piper Sandler Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Atara Biotherapeutics (ATRA) and Tempest Therapeutics (TPST)
Strong 3Q23 Results and Promising Clinical Developments Reinforce Buy Rating for Tempest Therapeutics
HC Wainwright & Co. : Maintain the Tempest Therapeutics (TPST.US) rating, adjusted from buy to buy rating, and adjust target price from $35.00 to $47.00.
Promising Prospects for Tempest Therapeutics: Buy Rating and Price Target Increase Based on Potential of TPST-1120
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Raises Price Target to $47
Tempest Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Tempest Therapeutics (TPST), Icecure Medical (ICCM)
Tempest Therapeutics Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Analysis
Price Target
No Data
